SCHEMBL10112988

SCHEMBL10112988

CCCCc1ccc(NC(=O)CNS(=O)(=O)C(C)C)cc1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.63
RAB9A P51151 3/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
POLB P06746 1/20 0.58
HPGD P15428 2/20 0.56
ALDH1A1 P00352 1/20 0.54
CA12 O43570 2/20 0.52
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
CA9 Q16790 2/20 0.52
GAA P10253 2/20 0.50
KDM4E B2RXH2 2/20 0.50
MAPT P10636 1/20 0.48
MAPK1 P28482 1/20 0.48
THRA P10827 1/20 0.48
THRB P10828 1/20 0.48
SPHK1 Q9NYA1 4/20 0.47
GALR3 O60755 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10112993 0.87 NPC1 (0.60) NPC1RAB9ASMN1; SMN2POLBHPGD
SCHEMBL10112985 0.86 NPC1 (0.59) NPC1RAB9ASMN1; SMN2POLBHPGD
SCHEMBL10112836 0.85 NPC1 (0.57) NPC1RAB9ASMN1; SMN2POLBHPGD
SCHEMBL10113003 0.84 NPC1 (0.56) NPC1RAB9ASMN1; SMN2POLBHPGD
SCHEMBL10112991 0.84 NPC1 (0.56) NPC1RAB9ASMN1; SMN2POLBHPGD
SCHEMBL10113152 0.80 KDM4E (0.65) NPC1RAB9ASMN1; SMN2POLBCA12
SCHEMBL10115350 0.79 HDAC6 (0.51) NPC1RAB9ASMN1; SMN2POLBHPGD
SCHEMBL10113189 0.78 THRA (0.52) NPC1RAB9ASMN1; SMN2POLBHPGD
SCHEMBL10112967 0.78 NPC1 (0.58) NPC1RAB9ASMN1; SMN2POLBHPGD
SCHEMBL9312715 0.78 POLB (0.84) NPC1RAB9ASMN1; SMN2POLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R NPC1 1435/4885RAB9A 3699/4885SMN1; SMN2 2213/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R NPC1 1353/4885RAB9A 3651/4885SMN1; SMN2 2197/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R NPC1 1462/4885RAB9A 3820/4885SMN1; SMN2 2251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.